Table 2.
Recent clinical applications of miR-192
| Refs | Disease | Origin | Samples | Tendency | Clinical Application |
|---|---|---|---|---|---|
| [13] | Cholangiocarcinoma (CCA) | Serum | 94 patients with cholangiocarcinoma undergoing tumour resection and 40 healthy controls | Up | Diagnosis and prognosis |
| [14] | CCA | Urinary | Urinary miR-192 level in healthy subjects (n = 21), O. viverrini-infected subjects (n = 24), subjects with periductal fibrosis (n = 28), CCA patients (n = 22) and patients with other inflammatory diseases (n = 10) | Up | Diagnosis |
| [15] | CCA | Serum | Serum from 11 CCA patients and nine healthy subjects | Up | Prognosis |
| [44] | Pediatric AML | Serum | The serum from 97 AML cases and 50 healthy controls | Down | Diagnosis and prognosis |
| [47] | CLL | PBMCs | PBMCs of CLL patients (n = 20) in comparison with healthy subjects (n = 20) | Down | Diagnosis and prognosis |
| [119] | Hepatocellular carcinoma (HCC) | Plasma exosome |
Exosomes derived from the plasma of 24 (14 early and 10 advanced) HCC patients, 37 liver cirrhosis patients and 20 HCs Exosomal levels from the plasma of 84 HCC patients, 50 liver cirrhosis patients, and 20 HCs |
Up | Diagnosis and prognosis |
| [42] | Colorectal cancer (CRC) | Serum | The serum of 164 colon cancer patients and 60 healthy controls | Down | Diagnosis and prognosis |
| [27] | CRC | Tissue | 16 Stage IIIB patients (8 patients with liver metastasis between 8 and 18 months after radical operation to remove their colon cancers.) and control (8 patients: 4 right colon cancer patients and 4 left colon cancer patients) groups | Down | Prognosis |
| [31] | CRC | tissue | 107 pairs of CRC tissues and non-tumor adjacent tissues | Down | Diagnosis |
| [52] | EOC | Plasma exosome | Plasma exosomes were isolated from peripheral blood of EOC patients and healthy donors | Down | Diagnosis and prognosis |
| [51] | Ovarian carcinoma | Tissue | 89 samples (53 high-grade serous carcinomas, 17 endometrioid carcinomas, 7 low-grade serous carcinomas, 5 clear cell carcinomas, 4 borderline tumors, and 3 mucinous carcinomas) |
Up (mucinous) Down (others) |
Diagnosis |
| [57] | Gastric cancer (GC) | Plasma exosome | The exosomal microRNAs (ex-miRNAs) were isolated from plasma samples from 60 gastric cancer (GC) patients and 63 healthy individuals | Up | Diagnosis and prognosis |
| [43] | GC | Tissue | 25 samples of gastric cancer and ANTs | Down | Diagnosis |
| [58] | GC | Plasma | Plasma levels in GC/DM samples (n = 48) compared with GC/NDM (n = 48) and HCs (n = 30) | Up | Diagnosis |
| [59] | GC | Tissue | 118 pairs of gastric cancer tissues and non-tumor counterparts (as controls) | Down | Diagnosis |
| [69] | PDAC | Tissue, serum, plasma exosome |
26 PDAC tissues vs 19 HCs and 26 ANTs serum of PDAC UICC stage IV vs. 19 HCs Serum exosomes of PDAC UICC stages II to IV vs. HCs |
Down (tissues) Up (serum, exosome) |
Diagnosis and prognosis |
| [68] | Pancreatic cancer (PC) | Serum | In serum of PC 74 patients with PC, 29 type 2 diabetic patients and 17 controls | Up | Diagnosis |
| [70] | PDAC | tissue, serum |
Pooled tissue extracts of 10 PDACs and adjacent normal controls (n = 10) Serum samples from PDAC patients (n = 70) compared to duodenal adenocarcinoma patients (n = 17) and healthy controls (n = 40) |
Up | Diagnosis |
| [16] | Cervical cancer | Tissue | 40 clinical cervical tissue samples containing 20 normal (Norm) and 20 adenocarcinoma (Tumor) tissue samples | Up | Diagnosis |
| [79] | prostate cancer (PCa) | Tissue | PCa tissues compared to nontumor tissues; metastatic samples compared to primary tumor tissues (TCGA、GEO) | Up | Diagnosis |
| [17] | HNSCC | Plasma exosome | In hypoxic sEVs compared with normoxic sEVs | Up | Diagnosis |
| [46] | Bladder cancer | Urine | Morning urine from bladder cancer (n = 118) and benign urinary system diseases (control, n = 120) | Down | Diagnosis |
| [73] | NSCLC | Bronchial lavage | Bronchial lavage samples from NSCLC participants and HCs (n = 100) | Down | Prognosis |
| [38] | Osteosarcoma | Tissue | 80 pairs of osteosarcoma and corresponding noncancerous bone tissues | Down | Prognosis |
| [122] | Larynx/HSCC | Tissue | Tumors of patients with late/no recurrence vs. patients with early recurrence | Down | Prognosis |
| [50] | Esophageal cancer (EC) | Tissue | 80 post-therapeutic samples of EC compared to corresponding pretherapeutic samples | Down | Prognosis |
HCs health controls, ANTs adjacent non-cancerous tissues, GC/DM gastric cancer with distant metastasis, GC/NDM gastric cancer with no distant metastasis, UICC Union for International Cancer Control